Research ArticleCancer

Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib

See allHide authors and affiliations

Science Translational Medicine  09 Aug 2017:
Vol. 9, Issue 402, eaam8060
DOI: 10.1126/scitranslmed.aam8060

Article Information

vol. 9 no. 402

Print ISSN: 
Online ISSN: 
  • Received for publication January 18, 2017
  • Resubmitted April 19, 2017
  • Accepted for publication June 29, 2017

Author Information

  1. Samuel J. Taylor1,
  2. Johanna M. Duyvestyn1,
  3. Samantha A. Dagger1,
  4. Emma J. Dishington1,
  5. Catherine A. Rinaldi1,
  6. Oliver M. Dovey2,
  7. George S. Vassiliou2,3,
  8. Carolyn S. Grove1,4,5 and
  9. Wallace Y. Langdon1,*
  1. 1School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia 6009, Australia.
  2. 2Department of Haematology, Cambridge University Hospitals NHS Trust, Cambridge CB2 0QQ, UK.
  3. 3Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  4. 4PathWest Department of Haematology, Queen Elizabeth II Medical Centre, Nedlands, Western Australia 6009, Australia.
  5. 5Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia.
  1. *Corresponding author. Email: wally.langdon{at}


Article usage

Aug 20178596313546
Sep 20176555771
Oct 20171481120